Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients.

Abstract

Deferasirox (DFRA) is a novel oral chelator agent for treatment of iron overload. Although well established in the treatment of β-thalassemia major (β-TM), it has not yet been fully investigated in patients with sickle cell disease. The aim of this report is to present the preliminary results of a pilot study assessing the effect of 4 years of DFRA treatment in six patients with sickle cell disease who are in need of recurrent transfusions. Our results show a significant reduction of ferritin levels and improvement of liver hemosiderosis, assessed by means of magnetic resonance imaging T2* (MRI T2*). None of the patients presented any serious adverse effects and the treatment was well tolerated. These results are in accordance with previous studies about the use of DFRA in sickle cell disease.

• Authors: Efthymia Vlachaki, Maria Mainou, Eleni Bekiari, Evaggelia Vetsiou, Apostolos Tsapas
• Journal: Hemoglobin (Hemoglobin) Vol. 37 Issue 1 Pg. 94-100 ( 2013) ISSN: 1532-432X [Electronic] England
• PMID: 23215738 (Publication Type: Journal Article)

Chemical References

• Benzoates
• Iron Chelating Agents
• Triazoles
• Ferritins
• Deferasirox

Topics

• Adult
• Anemia, Sickle Cell (blood, drug therapy, pathology)
• Benzoates (adverse effects, therapeutic use)
• Deferasirox
• Female
• Ferritins (blood)
• Humans
• Iron Chelating Agents (adverse effects, therapeutic use)
• Iron Overload (drug therapy)
• Liver (drug effects, pathology)
• Male
• Middle Aged
• Pilot Projects
• Triazoles (adverse effects, therapeutic use)